SRX Cardio, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Feb 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) Protein Activity (US 10,307,433) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Method to Treat Lipid Dysregulation by Modulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity with Small Molecule Ligands (US 11,771,710) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 2 fees due Aug 6 to 25, 2027 · next Aug 6
- 1 fee due Sep 12, 2027The maintenance fee for Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use (US 11,925,637) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 2 fees due Oct 2, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,287,317 | Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels In force · From the USPTO record | In force | From the USPTO record | |
| US 10,307,433 | Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) Protein Activity In force · High confidence | In force | High confidence | |
| US 10,688,114 | Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) Protein Activity In force · High confidence | In force | High confidence | |
| US 11,771,710 | Method to Treat Lipid Dysregulation by Modulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity with Small Molecule Ligands In force · High confidence | In force | High confidence | |
| US 10,568,882 | Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use In force · High confidence | In force | High confidence | |
| US 10,821,106 | Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity In force · High confidence | In force | High confidence | |
| US 11,925,637 | Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use In force · Medium confidence | In force | Medium confidence | |
| US 11,944,619 | Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity In force · High confidence | In force | High confidence | |
| US 11,891,369 | Compounds for Binding Proprotein Convertase Subtilisin/Kexin Type 9 In force · High confidence | In force | High confidence | |
| US 11,945,782 | Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 abandoned